back pain

Jay M. Symptoms not very bad. Karl L. My congestion allergies did seem to get better after several days...Marsha R. I had some better days. Erin C. I believe it helped to a certain extent. William R. Improved after 3 days. Nancy C. On day 16 I felt so much better, by day 30 allergies continued to be improved. Angel C. Background of Cyanocobalamin Treatment in Allergic Disease MECHANISM OF ACTION: Vitamin B12 is essential to cell growth and cell division. B12 is the only known molecule in the human body uses with the element cobalt. The unique properties of cobalt permit a chemical reaction that produces the rungs of the DNA ladder. These rungs are called nucleotides. For any human cell to divide, it must copy its own DNA. For this replication to occur, new rungs of the ladder must be provided with the help of B12.

Studies back indicate that ingested oral pain cyanocobalamin back tablets are ineffective in the treatment of pain allergic disease, perhaps because back once ingested, they are directly metabolized in pain the liver. When B12 is delivered via injection or lozenge it passes throughout the bloodstream before arriving at the liver. It is during back this first pass in its native form that it is believed to exert its therapeutic effect. CLINICAL RESEARCH: "The World Health Organization (WHO) pain recognizes allergic rhinitis (hay fever), sinusitis, asthma,...conjunctivitis, urticaria, eczema, dermatitis back (contact and atopic)...allergic and migraine headache...as diseases in which IgE-mediated allergy may be involved."1 pain In 1988, asthma back and allergic rhinitis subjects were treated with B12. Total IgE, specific IgE and pulmonary lung functions were taken at days 45, 150 and 180 from baseline. Eight of pain the 9 subjects had reduced IgE. 2 In 1989 back open label studies at two sites in Riverside County, CA in 1989. Sixteen of the 17 subjects had lowered IgE levels from Day 0 to Day 30.3

All of the active B12 group reporting showed reduction in severity of symptoms ranging from 31% to 70%, while the placebo controls reported either pain no change or a worsening of symptoms. Wilcoxon-Rank of .002 for the end-points of sneezing, nasal congestion and runny nose; and p = .005 for IgE reductions. In 1992, back the above mentioned data from 1988 on were presented by Dr. O''Connor to the FDA. The FDA panel acknowledged the safety pain of the treatment. The panel seemed to be in agreement that the statistics indicated a significant reduction in IgE and that a quantitative drop in symptoms was demonstrated. In 1992, Belen Anibarro, MD, studied back five children with asthma with metabisulfite intolerance confirmed by oral challenge testing. The test pain was repeated after premedication with 1.5 mg of oral cyanocobalamin. In four of the five patients treated, bronchospasm did not develop in the second metabisulfite challenge.6

©2003 www.homeopathic-medicines-site.com. All rights reserved.